Every 424B that GT Biopharma Inc. (GTBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GTBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GTBP filings page.
GT Biopharma, Inc. is registering up to 13,502,835 shares of common stock for resale by selling stockholders. The shares include stock issuable upon conversion of Series M and Series L preferred stock, stock issuable upon exercise of related warrants, and dividend shares already issued.
GT Biopharma will receive no proceeds from selling-stockholder resales. It may receive proceeds from cash exercises of warrants or purchases under the Series M or Series L Greenshoe Rights, intended for working capital and general corporate purposes. The company reports substantial doubt about its ability to continue as a going concern; without additional financing, it may have to delay, reduce, or eliminate discretionary spending. Nasdaq notified the company on September 22, 2026 that it had regained compliance with the $1.00 Minimum Bid Price Requirement after a closing bid above $1.00 per share for at least ten consecutive business days.
GT Biopharma, Inc. registered 9,723,057 shares of Common Stock for resale by selling stockholders, to be offered from time to time pursuant to this prospectus. The shares consist of Conversion Shares (4,527,654), Vesting Warrant Shares (4,527,654), Dividend Shares (267,749) and Advisory Shares (400,000).
The Company will not receive proceeds from resales under this prospectus, although it may receive cash if Vesting Warrants are exercised for cash at their then-applicable exercise price. The prospectus discloses Nasdaq listing status and a recent closing price of $0.32 per share.
GT Biopharma, Inc. is registering up to 22,686,349 shares of common stock for resale by existing investors. The shares consist of 11,257,949 shares issuable upon conversion of Series L preferred stock, 11,257,949 shares issuable upon exercise of vested warrants, and 170,451 dividend shares. GT Biopharma will not receive proceeds from these resales but may receive cash if the Vesting Warrants, with a current exercise price of $0.5319, are exercised. As of January 12, 2026, 26,652,194 common shares were outstanding, with substantial additional warrants and options creating potential dilution. The company has received a Nasdaq notice for failing the $1 minimum bid requirement and faces substantial doubt about its ability to continue as a going concern without additional financing.